Lineage Cell Therapeutics, Inc. (LCTX)
| Market Cap | 264.64M |
| Revenue (ttm) | 3.53M |
| Net Income (ttm) | -12.00M |
| Shares Out | 168.56M |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,136,870 |
| Open | 1.65 |
| Previous Close | 1.65 |
| Day's Range | 1.57 - 1.67 |
| 52-Week Range | 1.55 - 3.13 |
| Beta | 1.71 |
| Analysts | Buy |
| Price Target | 6.40 (+307.6%) |
| Earnings Date | n/a |
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute sp...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is 6.40, which is an increase of 307.64% from the latest price.
News
Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapi...
Why Lineage Cell Therapeutics Zoomed Higher Today
The biotech stands to reap hundreds of millions of dollars from a new collaboration with a top pharmaceutical player.
Hot Penny Stocks To Buy For Under $5 Right Now
Making a list of the best penny stocks to buy now? These 4 have turned heads in the stock market today.
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY) Genentech to develop and commercialize retina...
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpR...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neuroscie...
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and 305.36%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, ...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Analysts Estimate Lineage Cell (LCTX) to Report a Decline in Earnings: What to Look Out for
Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Micha...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christo...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical ...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. ...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Lineage Announces Appointment of General Counsel
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Lineage Cell (LCTX) Reports Q2 Loss, Misses Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and -51.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy P...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?
Image by Rudy and Peter Skitterians from Pixabay Age-related macular degeneration (AMD) is a disease originating in the retina, which may worsen over time, according to WebMD. It's said to be the lead...
Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With ...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Ri...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...